December 20, 2010 09:52 ET

CDEX Inc. Appoints Dr. James G. Stevenson to the CDEX Board of Directors

TUCSON, AZ--(Marketwire - December 20, 2010) -  CDEX Inc. (OTCBB: CEXI) (, a leading developer of chemical detection products, using patented technologies, for use in healthcare and security markets, announced the appointment of Dr. James G. Stevenson to its Board of Directors. Dr. Stevenson has been the Director of Pharmacy Services at the University of Michigan Health system since 1999 and replaces Thomas Payne who resigned from the Board on December 11, 2010.

Dr. Stevenson received his BS Pharmacy and PharmD degrees from Wayne State University. Since 1999, Dr. Stevenson has served as the Director of Pharmacy Services at the University of Michigan Health System and Professor and Associate Dean for Clinical Sciences at the University of Michigan College Of Pharmacy. From 1998 to 1991, Dr. Stevenson served as Director of Pharmacy Services at West Virginia University Hospitals and from 1991 to 1999 was the Director of Pharmacy Services for the 8-hospital Detroit Medical Center/Wayne State University. He received Pharmacist of the Year awards from both the Michigan Society of Health-system Pharmacists and the Michigan Pharmacists Association. He received the Distinguished Alumnus Award from the Wayne State University Pharmacy Alumni Association and the Joseph Oddis Leadership Award by MSHP. He recently completed a term of service on the Board of Directors of the American Society of Health-system Pharmacists and is the recipient of the 2010 John W. Webb Lecture Award. Dr. Stevenson serves as the medication safety section editor for the Joint Commission Journal on Quality and Patient Safety. His research interests are in pharmacy practice management, pharmacoeconomics, and medication safety. 

"I am pleased to join the Board of CDEX and look forward to working with my fellow directors to realize the full potential of CDEX's life changing technologies. The company has developed valuable technology that could save thousands of lives every year through prevention of medication errors in the clinical environment. CDEX has a strong technology platform and vast market opportunity in healthcare and security both of which are key components for the future success of the Company. As a practicing pharmacist I recognize the prospects of the company and I will work to ensure that the best interests of shareholders, healthcare providers, and patients are represented on the board," stated Dr. Stevenson.

"Dr. Stevenson brings additional expertise and credibility that correlates directly with the healthcare and clinical markets we are targeting for our ValiMed systems. His insight and healthcare industry relationships will be crucial to gaining market penetration for our fourth generation of the ValiMed™ Validation System. The ValiMed G4 raises the bar for patient medication safety and pharmaceutical drug loss prevention, providing cutting edge features and benefits over existing systems available in the market. The G4 identifies the drug, the dose, the diluents, and is the first system to feature multi-component compound detection. The G4 is able to perform non-invasive measures of compounds directly through IV bags, syringes and vials, offering lower risk of contamination with increased workflow. We look forward to working with Dr. Stevenson and the other directors towards the common goal of delivering life changing technologies to our customers and creating value for our shareholders," stated Jeff Brumfield, CEO and Chairman of CDEX Inc.

About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Contact Information